Vicore Pharma (STO: VICO), a Swedish pharma company seeking to unlock the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), has announced that Bertil Lindmark will join as chief medical officer.
Dr Lindmark's career spans global leadership roles at major pharma and biotech companies. Formerly global vice president, clinical development for Respiratory and Inflammation at Anglo-Swedish drugmaker AstraZeneca (LSE: AZN), Dr Lindmark spearheaded the development of Symbicort (budesonide/formoterol) and Pulmicort (budesonide), among other globally renowned respiratory medicines.
As head of R&D at Spanish drugmaker Almirall (BME: ALM), his efforts led to the global approval of a second-to-market long acting antimuscarinic for the treatment of chronic obstructive pulmonary disease (COPD).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze